Exercise: 1 hour of one-legged knee-extensor exercise followed by 4 hours of rest
Insulin infusion: 2 hours of Euglycemic Hyperinsulinemic Clamp
Placebo: Administration of 800 mg of calcium tablets
Rapamycin: Administration of 16 mg of Rapamycin tablets
Study summary
The study investigates the role of mTOR in mediating enhancement of muscle insulin sensitivity following a single bout of exercise.
This will be investigated in young healthy male subjects by administering the pharmacological mTOR inhibitor Rapamycin in a crossover blinded experimental setup known to enhance muscle insulin sensitivity following one-legged knee-extensor exercise.
Eligibility
Sex
MALE
Min age
22 Years
Max age
35 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Healthy persons (no known disease) without diabetes in the family
* No use of medications
* Non-smokers
* Men
* Age 22-35 years
* Physical activity level (VO2peak) between 30-50 mL O2/min/kg
* BMI between 18.0 and 25.0
Exclusion Criteria:
* Women
* Physical activity (e.g., running, cycling, fitness, etc.) above 6 hours a week.
* Persons who show signs of metabolic diseases, hematologic diseases, reduced liver function, human immunodeficiency virus (HIV), hepatitis, thyroid diseases or other signs of disease that may affect the outcome of the study or the study subject's wellbeing will be excluded.
* Acute sickness less than 2 weeks prior to study start.
* If disease appears or is identified and/or a need for medication arises after inclusion but before initiation of the study.
Disease during conclusion of the study
Primary outcome measure(s)
Insulin stimulated muscle glucose uptake — Through study completion, approx. 1 year. Muscle glucose uptake during insulin stimulation in recovery from exercise (insulin sensitivity) will be determined based on Fick's principle. Thus, femoral arterio-venous difference (av difference) in blood glucose concentration will be multiplied by femoral arterial leg blood flow.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
